MENU
FTXH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

FTXH stock forecast, quote, news & analysis

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index... Show more

Category: #Health
FTXH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for FTXH with price predictions
Jun 02, 2026

FTXH in upward trend: price may jump up because it broke its lower Bollinger Band on April 27, 2026

FTXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where FTXH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 21, 2026. You may want to consider a long position or call options on FTXH as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for FTXH crossed bullishly above the 50-day moving average on May 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 274 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where FTXH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FTXH turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

FTXH moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), ZOETIS (NYSE:ZTS).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF ETF is 59.38B. The market cap for tickers in the group ranges from 1.45B to 961.99B. LLY holds the highest valuation in this group at 961.99B. The lowest valued company is PRGO at 1.45B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 14%. For the same ETF, the average monthly price growth was 46%, and the average quarterly price growth was 88%. CORT experienced the highest price growth at 18%, while MDGL experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 6%. For the same stocks of the ETF, the average monthly volume growth was -2% and the average quarterly volume growth was -11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 60
Price Growth Rating: 49
SMR Rating: 65
Profit Risk Rating: 64
Seasonality Score: 35 (-100 ... +100)
View a ticker or compare two or three
FTXH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Wheaton
Phone
N/A
Web
www.ftportfolios.com
FTXH in upward trend: price may jump up because it broke its lower Bollinger Band on April 27, 2026